Indian J Pharm Close
 

Figure 1: Percentage of grade ≥3 adverse reactions with erlotinib, gefitinib, afatinib, and osimertinib

Figure 1: Percentage of grade ≥3 adverse reactions with erlotinib, gefitinib, afatinib, and osimertinib